Motesanib, or open-label bevacizumab, in combination with paclitaxel, as first-line treatment for HER2-negative locally recurrent or metastatic breast cancer: a phase 2, randomised, double-blind, placebo-controlled study

✍ Scribed by Miguel Martin; Henri Roche; Tamas Pinter; John Crown; M John Kennedy; Louise Provencher; Frank Priou; Wolfgang Eiermann; Encarna Adrover; Istvan Lang; Manuel Ramos; Jean Latreille; Agnieszka Jagiełło-Gruszfeld; Tadeusz Pienkowski; Emilio Alba; Raymond Snyder; Sachin Almel; Janusz Rolski; Montserrat Munoz; Rebecca Moroose; Sara Hurvitz; Ana Baños; Henry Adewoye; Yong-Jiang Hei; Mary-Ann Lindsay; Matthieu Rupin; David Cabaribere; Yasmin Lemmerick; John R Mackey

• Book ID: 117785594
• Publisher: The Lancet
• Year: 2011
• Tongue: English
• Weight: 230 KB
• Volume: 12
• Category: Article
• ISSN: 1470-2045
• DOI: 10.1016/s1470-2045(11)70037-7